(Q37804497)

23 August 2017

title

The next step in gene delivery: molecular engineering of adeno-associated virus serotypes (English)

1 reference

23 August 2017

Jinhui Wang

1

1 reference

23 August 2017

Susan M Faust

series ordinal

2

1 reference

23 August 2017

Joseph E Rabinowitz

series ordinal

3

1 reference

23 August 2017

publication date

26 October 2010

1 reference

Journal of Molecular and Cellular Cardiology

23 August 2017

published in

1 reference

23 August 2017

volume

50

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

793-802

1 reference

ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Epidemiology of adenovirus-associated virus infection in a nursery population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Immune responses to adenovirus and adeno-associated virus in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Targeted integration of adeno-associated virus (AAV) into human chromosome 19

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

AAV serotype 2 vectors preferentially integrate into active genes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

New recombinant serotypes of AAV vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Receptor targeting of adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Identification of PDGFR as a receptor for AAV-5 transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A viral phospholipase A2 is required for parvovirus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Notch1 augments intracellular trafficking of adeno-associated virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Characterization of a nuclear localization signal of canine parvovirus capsid proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Release of canine parvovirus from endocytic vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Real-time single-molecule imaging of the infection pathway of an adeno-associated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Can genes transduced by adeno-associated virus vectors elicit or evade an immune response?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

One year transgene expression with adeno-associated virus cardiac gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Gene therapy for hemophilia: clinical trials and technical tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

CD8(+) T-cell responses to adeno-associated virus capsid in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Hepatic AAV gene transfer and the immune system: friends or foes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Tailoring the AAV vector capsid for gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Tolerance induction by viral in vivo gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Gene therapy for haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Clinical gene transfer studies for hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Preclinical and clinical gene therapy for haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Immune implications of gene therapy for hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Clinical gene therapy using recombinant adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Effect of gene therapy on visual function in Leber's congenital amaurosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Safety and efficacy of gene transfer for Leber's congenital amaurosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Immune responses to AAV in a phase I study for Canavan disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Insertional mutagenesis of AAV2 capsid and the production of recombinant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Structure determination of adeno-associated virus 2: three complete virus particles per asymmetric unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

The epitope recognized by rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Peptides targeting caspase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

In vivo phage display and vascular heterogeneity: implications for targeted medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Chapter 4. Screening phage-display Peptide libraries for vascular targeted peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Steps toward mapping the human vasculature by phage display.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Organ targeting in vivo using phage display peptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

In vitro selection of viral vectors with modified tropism: the adeno-associated virus display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Isolation of targeted AAV2 vectors from novel virus display libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Yeast surface display for screening combinatorial polypeptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Inverting enantioselectivity by directed evolution of hydantoinase for improved production of L-methionine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Rapid evolution of a protein in vitro by DNA shuffling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Molecular breeding of viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Directed evolution of adeno-associated virus for glioma cell transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Chimeric AAV Cap sequences alter gene transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Ligand-directed targeting of genes to the site of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

New approaches in the therapy of cardiomyopathy in muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Self-complementary AAV vectors; advances and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

Adeno-associated virus general transduction vectors: analysis of proviral structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.10.017

7 January 2021

10.1016/J.YJMCC.2010.10.017

Identifiers

DOI

1 reference

23 August 2017

1 reference